377 related articles for article (PubMed ID: 28870238)
1. BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells.
Campbell AE; Oliva J; Yates MP; Zhong JW; Shadle SC; Snider L; Singh N; Tai S; Hiramuki Y; Tawil R; van der Maarel SM; Tapscott SJ; Sverdrup FM
Skelet Muscle; 2017 Sep; 7(1):16. PubMed ID: 28870238
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase A activation inhibits
Cruz JM; Hupper N; Wilson LS; Concannon JB; Wang Y; Oberhauser B; Patora-Komisarska K; Zhang Y; Glass DJ; Trendelenburg AU; Clarke BA
J Biol Chem; 2018 Jul; 293(30):11837-11849. PubMed ID: 29899111
[TBL] [Abstract][Full Text] [Related]
3. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.
Oliva J; Galasinski S; Richey A; Campbell AE; Meyers MJ; Modi N; Zhong JW; Tawil R; Tapscott SJ; Sverdrup FM
J Pharmacol Exp Ther; 2019 Aug; 370(2):219-230. PubMed ID: 31189728
[TBL] [Abstract][Full Text] [Related]
4. Expression patterns of FSHD-causing DUX4 and myogenic transcription factors PAX3 and PAX7 are spatially distinct in differentiating human stem cell cultures.
Haynes P; Kernan K; Zhou SL; Miller DG
Skelet Muscle; 2017 Jun; 7(1):13. PubMed ID: 28637492
[TBL] [Abstract][Full Text] [Related]
5. p38
Rojas LA; Valentine E; Accorsi A; Maglio J; Shen N; Robertson A; Kazmirski S; Rahl P; Tawil R; Cadavid D; Thompson LA; Ronco L; Chang AN; Cacace AM; Wallace O
J Pharmacol Exp Ther; 2020 Sep; 374(3):489-498. PubMed ID: 32576599
[TBL] [Abstract][Full Text] [Related]
6. Influence of
Duranti E; Villa C
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298453
[TBL] [Abstract][Full Text] [Related]
7. Sporadic DUX4 expression in FSHD myocytes is associated with incomplete repression by the PRC2 complex and gain of H3K9 acetylation on the contracted D4Z4 allele.
Haynes P; Bomsztyk K; Miller DG
Epigenetics Chromatin; 2018 Aug; 11(1):47. PubMed ID: 30122154
[TBL] [Abstract][Full Text] [Related]
8. Nuclear bodies reorganize during myogenesis in vitro and are differentially disrupted by expression of FSHD-associated DUX4.
Homma S; Beermann ML; Yu B; Boyce FM; Miller JB
Skelet Muscle; 2016 Dec; 6(1):42. PubMed ID: 27906075
[TBL] [Abstract][Full Text] [Related]
9. DUX4 binding to retroelements creates promoters that are active in FSHD muscle and testis.
Young JM; Whiddon JL; Yao Z; Kasinathan B; Snider L; Geng LN; Balog J; Tawil R; van der Maarel SM; Tapscott SJ
PLoS Genet; 2013 Nov; 9(11):e1003947. PubMed ID: 24278031
[TBL] [Abstract][Full Text] [Related]
10. DUX4-induced constitutive DNA damage and oxidative stress contribute to aberrant differentiation of myoblasts from FSHD patients.
Dmitriev P; Bou Saada Y; Dib C; Ansseau E; Barat A; Hamade A; Dessen P; Robert T; Lazar V; Louzada RAN; Dupuy C; Zakharova V; Carnac G; Lipinski M; Vassetzky YS
Free Radic Biol Med; 2016 Oct; 99():244-258. PubMed ID: 27519269
[TBL] [Abstract][Full Text] [Related]
11. Direct interplay between two candidate genes in FSHD muscular dystrophy.
Ferri G; Huichalaf CH; Caccia R; Gabellini D
Hum Mol Genet; 2015 Mar; 24(5):1256-66. PubMed ID: 25326393
[TBL] [Abstract][Full Text] [Related]
12. The FSHD atrophic myotube phenotype is caused by DUX4 expression.
Vanderplanck C; Ansseau E; Charron S; Stricwant N; Tassin A; Laoudj-Chenivesse D; Wilton SD; Coppée F; Belayew A
PLoS One; 2011; 6(10):e26820. PubMed ID: 22053214
[TBL] [Abstract][Full Text] [Related]
13. Deciphering transcription dysregulation in FSH muscular dystrophy.
Ehrlich M; Lacey M
J Hum Genet; 2012 Aug; 57(8):477-84. PubMed ID: 22718021
[TBL] [Abstract][Full Text] [Related]
14. Model systems of DUX4 expression recapitulate the transcriptional profile of FSHD cells.
Jagannathan S; Shadle SC; Resnick R; Snider L; Tawil RN; van der Maarel SM; Bradley RK; Tapscott SJ
Hum Mol Genet; 2016 Oct; 25(20):4419-4431. PubMed ID: 28171552
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the double homeodomain protein DUX4c interferes with myofibrillogenesis and induces clustering of myonuclei.
Vanderplanck C; Tassin A; Ansseau E; Charron S; Wauters A; Lancelot C; Vancutsem K; Laoudj-Chenivesse D; Belayew A; Coppée F
Skelet Muscle; 2018 Jan; 8(1):2. PubMed ID: 29329560
[TBL] [Abstract][Full Text] [Related]
16. A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy.
Gatica LV; Rosa AL
Neuromuscul Disord; 2016 Dec; 26(12):844-852. PubMed ID: 27816329
[TBL] [Abstract][Full Text] [Related]
17. PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level.
Banerji CRS; Zammit PS
Hum Mol Genet; 2019 Jul; 28(13):2224-2236. PubMed ID: 31067297
[TBL] [Abstract][Full Text] [Related]
18. DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy?
Tassin A; Laoudj-Chenivesse D; Vanderplanck C; Barro M; Charron S; Ansseau E; Chen YW; Mercier J; Coppée F; Belayew A
J Cell Mol Med; 2013 Jan; 17(1):76-89. PubMed ID: 23206257
[TBL] [Abstract][Full Text] [Related]
19. PAX7 target genes are globally repressed in facioscapulohumeral muscular dystrophy skeletal muscle.
Banerji CRS; Panamarova M; Hebaishi H; White RB; Relaix F; Severini S; Zammit PS
Nat Commun; 2017 Dec; 8(1):2152. PubMed ID: 29255294
[TBL] [Abstract][Full Text] [Related]
20. β-Catenin is central to DUX4-driven network rewiring in facioscapulohumeral muscular dystrophy.
Banerji CR; Knopp P; Moyle LA; Severini S; Orrell RW; Teschendorff AE; Zammit PS
J R Soc Interface; 2015 Jan; 12(102):20140797. PubMed ID: 25551153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
